12. Subsequent Events	6 Months Ended
Jun. 30, 2016
Notes to Financial Statements
12. Subsequent Events	On July 1, 2016, the Company issued 5,750,000 shares of $0.001 par value Common Stock in exchange for services. On July 1, 2016, the Company executed a Convertible Promissory Note payable having a face value of $55,000.00. The proceeds from this Note were received by the Company on June 30, 2016 and were recorded in the Financial Statements as Current Liability. On July 1, 2016, the Company executed a Convertible Promissory Note payable having a face value of $174,852.00 comprised of the principal amount ($165,000) and all accrued interest ($9,852) on the Convertible Promissory Note payable that matured on June 30, 2016 (see Note 4). On July 6, 2016, the Company amended its Articles of Incorporation, increasing its authorized capital to 3,000,000,000 shares of Common Stock, $0.001 par value per share, and 30,000,000 shares of Preferred Stock, $0.10 par value per share. On July 8, 2016, the Company issued 321,305,416 shares of $0.001 par value Common Stock to Advanomics Corporation (“Advanomics”), a related party, in exchange for cancellation of the two notes payable specified above under Note 5 totaling $835,394 held by Advanomics.

12. Subsequent Events

6 Months Ended

Jun. 30, 2016

On July 1, 2016, the Company issued 5,750,000 shares of $0.001 par value Common Stock in exchange for services.

On July 1, 2016, the Company executed a Convertible Promissory Note payable having a face value of $55,000.00. The proceeds from this Note were received by the Company on June 30, 2016 and were recorded in the Financial Statements as Current Liability.

On July 1, 2016, the Company executed a Convertible Promissory Note payable having a face value of $174,852.00 comprised of the principal amount ($165,000) and all accrued interest ($9,852) on the Convertible Promissory Note payable that matured on June 30, 2016 (see Note 4).

On July 6, 2016, the Company amended its Articles of Incorporation, increasing its authorized capital to 3,000,000,000 shares of Common Stock, $0.001 par value per share, and 30,000,000 shares of Preferred Stock, $0.10 par value per share.

On July 8, 2016, the Company issued 321,305,416 shares of $0.001 par value Common Stock to Advanomics Corporation (“Advanomics”), a related party, in exchange for cancellation of the two notes payable specified above under Note 5 totaling $835,394 held by Advanomics.